165 related articles for article (PubMed ID: 11862534)
1. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
[TBL] [Abstract][Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
3. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
4. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
5. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
6. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
7. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
8. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
10. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
11. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
Garnero P; Christgau S; Delmas PD
Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
[TBL] [Abstract][Full Text] [Related]
12. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
Rousseau JC; Chevrel G; Schott AM; Garnero P
Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
[TBL] [Abstract][Full Text] [Related]
14. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
Cloos PA; Fledelius C
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504
[TBL] [Abstract][Full Text] [Related]
15. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
16. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
17. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of bone turnover in Paget's disease of bone.
Delmas PD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
[TBL] [Abstract][Full Text] [Related]
19. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
20. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
